01 Growing Adoption of Faster and Ready-to-Use Hemostatic Products Surgical teams are increasingly favoring hemostatic products that require minimal preparation and can be applied quickly during unexpected or difficult-to-control bleeding. Flowable matrices, powders, patches, and ready-to-use formulations can reduce preparation steps while improving access to irregular or difficult-to-reach surgical sites. This shift is particularly important in cardiovascular, orthopedic, general, and minimally invasive procedures, where operating-room efficiency and rapid bleeding control are critical. These developments are strengthening hemostasis & tissue sealing agents market trends as manufacturers focus on products combining easier preparation with reliable clinical performance. In June 2026, Johnson & Johnson MedTech launched its new SURGIFLO Hemostatic Matrix Kit with Thrombin. The redesigned system is 36% faster to prepare than the previous SURGIFLO configuration and more than 2.5 times faster than a leading competing product, supporting quicker preparation during surgical procedures.
02 Increasing Development of Flowable Hemostats for Difficult-to-Reach Bleeding Manufacturers are expanding beyond conventional sheets and sponges toward flowable and conformable hemostatic products. Growing preference for adaptable delivery formats is increasing hemostasis & tissue sealing agents market demand across different surgical specialties. In February 2026, BD reported the U.S. launch of Avitene Flowable, a fluid, space-filling hemostatic agent developed for bleeding in difficult-to-visualize or difficult-to-reach areas. The launch moved BD into a hemostatic segment valued at nearly USD 400 million and growing at approximately 5%, while using microfibrillar collagen technology without requiring additional biologics.
01 Increasing Surgical Complexity Strengthens Demand for Advanced Bleeding Control Hemostatic agents provide surgeons with additional methods to accelerate clot formation and control bleeding across irregular surfaces, while tissue sealants can reinforce closures and prevent fluid or air leakage. Increasing adoption of sophisticated surgical procedures is therefore supporting hemostasis & tissue sealing agents market growth and encouraging broader use of advanced adjunctive products.
01 Complex Regulatory Requirements Can Slow Product Commercialization Hemostatic and tissue-sealing products can contain biological, collagen-based, synthetic, or combination materials, requiring manufacturers to demonstrate safety, effectiveness, biocompatibility, manufacturing consistency, and appropriate clinical performance. Regulatory requirements become particularly demanding for products containing human- or animal-derived components. These development and approval requirements can increase commercialization costs and extend product-development timelines, potentially limiting expansion of the hemostasis & tissue sealing agents market size, especially for smaller manufacturers.
01 Investment in Established Biosurgery Platforms Creates Expansion Opportunities Established hemostatic and tissue-sealing technologies provide opportunities for companies and investors to expand into new surgical specialties, geographic markets, and clinical indications. Products supported by substantial clinical evidence can also serve as platforms for developing broader biosurgery portfolios. Investment in these technologies can accelerate commercialization, distribution expansion, and additional product innovation, creating opportunities for participants to strengthen their hemostasis & tissue sealing agents market share.
01 Achieving Reliable Hemostasis Across Different Bleeding Conditions Remains Difficult The hemostasis & tissue sealing agents industry must address substantial differences in bleeding severity, surgical anatomy, coagulation status, tissue characteristics, and accessibility of the bleeding site. A product effective for diffuse capillary bleeding may not provide the same performance for higher-pressure vascular bleeding or tissue leakage. Manufacturers therefore need multiple formulations, delivery mechanisms, and product configurations while ensuring that surgeons can select and apply the appropriate solution efficiently during procedures.
June 2026 Johnson & Johnson MedTech expanded its surgical solutions portfolio by advancing hemostatic agents and tissue management technologies. The company focused on improving surgical bleeding control, procedural efficiency, and patient outcomes across complex surgeries.
May 2026 Baxter expanded its surgical care portfolio by advancing hemostasis and tissue sealing solutions designed for operating room applications. The initiatives focused on improving bleeding management, surgical workflow efficiency, and patient recovery.
April 2026 Medtronic expanded its surgical technologies portfolio through advancements in hemostatic products and tissue sealing solutions. The company focused on developing innovative surgical tools to support effective bleeding control and minimally invasive procedures.
January 2026 BD (Becton, Dickinson and Company) expanded its surgical solutions capabilities through continued development of advanced surgical products, including technologies supporting wound management and procedural efficiency.